» Articles » PMID: 22386743

Comparative in Vitro Activity of Carbapenems Against Major Gram-negative Pathogens: Results of Asia-Pacific Surveillance from the COMPACT II Study

Overview
Date 2012 Mar 6
PMID 22386743
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

Resistance rates amongst Gram-negative pathogens are increasing in the Asia-Pacific region. The Comparative Activity of Carbapenem Testing (COMPACT) II study surveyed the carbapenem susceptibility and minimum inhibitory concentrations (MICs) of doripenem, imipenem and meropenem against 1260 major Gram-negative pathogens isolated from hospitalised patients at 20 centres in five Asia-Pacific countries (New Zealand, the Philippines, Singapore, Thailand and Vietnam) during 2010. Pseudomonas aeruginosa (n=625), Enterobacteriaceae (n=500), and other Gram-negative pathogens including Acinetobacter baumannii (n=135) were collected from patients with bloodstream infection (32.2%), nosocomial pneumonia including ventilator-associated pneumonia (58.1%), and complicated intra-abdominal infection (9.7%), with 36.7% being isolated from patients in an Intensive Care Unit. As high as 29.8% of P. aeruginosa and 73.0% of A. baumannii isolates were not susceptible to at least a carbapenem, whereas the majority of Enterobacteriaceae (97.2%) were susceptible to all carbapenems. Respective MIC(50)/MIC(90) values (MICs for 50% and 90% of the organisms, respectively) of doripenem, imipenem and meropenem were: 0.38/8, 1.5/32 and 0.38/16 mg/L for P. aeruginosa; 0.023/0.094, 0.25/0.5 and 0.032/0.094 mg/L for Enterobacteriaceae; and 32/64, 32/128 and 32/64 mg/L for A. baumannii. Doripenem and meropenem had comparable activity against P. aeruginosa, both being more active than imipenem. All carbapenems were highly potent against Enterobacteriaceae, although imipenem demonstrated higher MIC values than doripenem and meropenem. The three carbapenems showed less activity against A. baumannii. The high prevalence of carbapenem resistance amongst important nosocomial pathogens (P. aeruginosa and A. baumannii) warrants rigorous infection control measures and appropriate antimicrobial use in the Asia-Pacific region.

Citing Articles

Risk factors for progression to bacteremia among patients with nosocomial carbapenem-resistant Acinetobacter baumannii pneumonia in the Intensive Care Unit.

Niu H, Shen X, Liang H, Wu G, Cai S, Shen Q Eur J Clin Microbiol Infect Dis. 2023; 42(11):1337-1346.

PMID: 37768395 PMC: 10587305. DOI: 10.1007/s10096-023-04668-9.


Molecular characterization of multidrug-resistant ESKAPEE pathogens from clinical samples in Chonburi, Thailand (2017-2018).

Ruekit S, Srijan A, Serichantalergs O, Margulieux K, Mc Gann P, Mills E BMC Infect Dis. 2022; 22(1):695.

PMID: 35978294 PMC: 9386987. DOI: 10.1186/s12879-022-07678-8.


Optimizing Antimicrobial Therapy by Integrating Multi-Omics With Pharmacokinetic/Pharmacodynamic Models and Precision Dosing.

Yow H, Govindaraju K, Lim A, Abdul Rahim N Front Pharmacol. 2022; 13:915355.

PMID: 35814236 PMC: 9260690. DOI: 10.3389/fphar.2022.915355.


Risk Factors for and Clinical Outcomes of Polymicrobial Bloodstream Infections.

Qian Z, Zhang S, Li N, Ma W, Zhang K, Song F Biomed Res Int. 2022; 2022:5122085.

PMID: 35265714 PMC: 8898812. DOI: 10.1155/2022/5122085.


Genomic surveillance of in the Philippines, 2013-2014.

Chilam J, Argimon S, Limas M, Masim M, Gayeta J, Lagrada M Western Pac Surveill Response J. 2022; 12(4):1-15.

PMID: 35251744 PMC: 8873916. DOI: 10.5365/wpsar.2021.12.4.863.